
Please try another search
(Reuters) - Medical device maker Becton Dickinson and Co (N:BDX) beat quarterly profit estimates on Thursday, aided by higher demand for its COVID-19 diagnostic test kits as the United States ramped up testing for the new coronavirus.
The country, which has recorded at least 158,561 COVID-19 deaths and about 4.8 million cases so far, is running only 800,000 diagnostic coronavirus tests daily, while 6-10 million tests per day are needed, by various estimates.
Revenue in Becton's diagnostics systems unit rose nearly 19% to $184 million, the company said.
Becton Dickinson, which sells a variety of COVID-19 tests, said it was working to ramp up testing capacity for many of them in the event of a second wave of infections in the fall.
The company also benefited from orders received from the United States, UK and Canada for millions of its syringes and needles for COVID-19 vaccination programs.
Excluding items, the company earned $2.20 per share, beating analysts' estimates of $2.04 per share, according to IBES data from Refinitiv.
Sales fell to $3.86 billion from $4.35 billion, compared with the average analyst estimate of $3.94 billion.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.